|
| 37986556 | A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma. | BJU Int | 2024 |
| 36675126 | ProNGF Expression and Targeting in Glioblastoma Multiforme. | Int J Mol Sci | 2023 |
| 37841696 | NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. | Neurooncol Adv | 2023 |
| 35849035 | Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. | Neuro Oncol | 2023 |
| 37151848 | Targeting XBP1 mRNA splicing sensitizes glioblastoma to chemotherapy. | FASEB Bioadv | 2023 |
| 37451291 | Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. | Lancet Oncol | 2023 |
| 37173980 | The Membrane Protein Sortilin Is a Potential Biomarker and Target for Glioblastoma. | Cancers (Basel) | 2023 |
| 36872949 | Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). | Ther Adv Med Oncol | 2023 |
| 34326127 | <sup>177</sup>Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. | J Nucl Med | 2022 |
| 35598359 | Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. | Eur J Cancer | 2022 |
| 36528772 | Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group). | BMC Cancer | 2022 |
| 36104135 | Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma. | BMJ Open | 2022 |
| 35091440 | Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). | Clin Cancer Res | 2022 |
| 35051527 | Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomes. | Biochim Biophys Acta Rev Cancer | 2022 |
| 34595697 | Identifying the unmet supportive care needs of people affected by kidney cancer: a systematic review. | J Cancer Surviv | 2022 |
| 34047023 | Business as unusual: medical oncology services adapt and deliver during COVID-19. | Intern Med J | 2021 |
| 33835866 | Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice. | J Urol | 2021 |
| 35096405 | What matters for people with brain cancer? Selecting clinical quality indicators for an Australian Brain Cancer Registry. | Neurooncol Pract | 2021 |
| 33968759 | A Novel Role for Brain and Acute Leukemia Cytoplasmic (BAALC) in Human Breast Cancer Metastasis. | Front Oncol | 2021 |
| 34056607 | Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. | Neurooncol Adv | 2021 |
| 34028967 | ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). | BJU Int | 2021 |
| 34357791 | How to Feel Bad. | J Clin Oncol | 2021 |
| 32257282 | Driving innovation through collaboration: development of clinical annotation datasets for brain cancer biobanking. | Neurooncol Pract | 2020 |
| 33271099 | Drug repurposing in oncology. | Lancet Oncol | 2020 |
| 32801017 | Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. | Ann Oncol | 2020 |
| 32340151 | Can Hemp Help? Low-THC Cannabis and Non-THC Cannabinoids for the Treatment of Cancer. | Cancers (Basel) | 2020 |
| 32245446 | Stem/progenitor cell marker expression in clear cell renal cell carcinoma: a potential relationship with the immune microenvironment to be explored. | BMC Cancer | 2020 |
| 32522746 | Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. | Clin Microbiol Rev | 2020 |
| 29573159 | Patients' experiences and preferences for opt-in models and health professional involvement in biobanking consent: A cross-sectional survey of Australian cancer outpatients. | Asia Pac J Clin Oncol | 2019 |
| 31775768 | The precursor for nerve growth factor (proNGF) is not a serum or biopsy-rinse biomarker for thyroid cancer diagnosis. | BMC Endocr Disord | 2019 |
| 31775361 | The Precursor for Nerve Growth Factor (proNGF) in Thyroid Cancer Lymph Node Metastases: Correlation with Primary Tumour and Pathological Variables. | Int J Mol Sci | 2019 |
| 31339636 | ANZUP MDT Masterclass Convenor Welcome. | Asia Pac J Clin Oncol | 2019 |
| 30910346 | Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. | Eur Urol | 2019 |
| 30656607 | The RANK-RANKL axis: an opportunity for drug repurposing in cancer? | Clin Transl Oncol | 2019 |
| 30575428 | Research Perspective on Utilizing and Valuing Tumor Biobanks. | Biopreserv Biobank | 2019 |
| 30425003 | Results of a Prospective Phase 2 Pilot Trial of <sup>177</sup>Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression. | Clin Genitourin Cancer | 2019 |
| 29223480 | Enlisting the willing: A study of healthcare professional-initiated and opt-in biobanking consent reveals improvement opportunities throughout the registration process. | Eur J Cancer | 2018 |
| 30209152 | Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). | BMJ Open | 2018 |
| 29476593 | Cell-Free DNA Blood Collection Tubes Are Appropriate for Clinical Proteomics: A Demonstration in Colorectal Cancer. | Proteomics Clin Appl | 2018 |
| 27684455 | Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy. | J Immunother | 2017 |
| 28475899 | An Immune Atlas of Clear Cell Renal Cell Carcinoma. | Cell | 2017 |
| 28351942 | Targeting the TSH receptor in thyroid cancer. | Endocr Relat Cancer | 2017 |
| 26893783 | Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. | Oncol Lett | 2016 |
| 26514153 | Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro. | Stem Cell Rev Rep | 2016 |
| 27701388 | Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. | Br J Cancer | 2016 |
| 27121191 | Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinoma. | Sci Rep | 2016 |
| 27422173 | Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicine. | BMC Cancer | 2016 |
| 27245079 | Current and Evolving Methods to Visualize Biological Data in Cancer Research. | J Natl Cancer Inst | 2016 |
| 27125797 | Forsaking cures for cancer: why are we discarding the tumour biospecimens of most patients? | Med J Aust | 2016 |
| 25444021 | Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities. | Intern Med J | 2015 |